Advertisement
Home »

Mepolizumab Improves Histologic Severity for Eosinophilic Esophagitis

Jun 17, 2024

REFERENCES & ADDITIONAL READING

Dellon E, et al. Mepolizumab improves histologic severity as measured by the EoE-HSS in adolescents and adults with eosinophilic esophagitis in a multicenter, randomized, double-blind, placebo-controlled clinical trial. Sa1284. Presented at: DDW 2024, May 18-21, 2024, Washington, DC.

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement